Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2005-6-16
pubmed:abstractText
Activation of telomerase, a key event during immortalization and malignant transformation, requires expression of the telomerase reverse transcriptase (hTERT). Consistently, lack of telomerase activity and hTERT expression occurs in most normal human somatic cells. However, it has been observed that both normal and cancerous renal tissues express hTERT whereas only the latter exhibits telomerase activity. The mechanism underlying the dissociation between hTERT expression and telomerase activity is unclear. In the present study, we examined telomerase activity and alternative splicing of hTERT transcripts in renal cell carcinoma (RCC) specimens and adjacent normal tissues from 33 patients with RCC. Telomerase activity was detectable in 27 of 33 (82%) RCC samples but none in their normal counterparts. Thirty-two of 33 tumors expressed overall hTERT mRNA and 27 of them contained full-length hTERT transcripts, all with telomerase activity. Although 42% (14 of 33) of normal renal samples expressed hTERT mRNA, none of them had full-length hTERT transcripts, coinciding with lack of telomerase activity. The presence of full-length hTERT mRNA and telomerase activity was significantly associated with c-MYC induction. In tumors, absence of full-length hTERT mRNA or telomerase activity defines a subgroup of nonmetastatic, early-stage RCCs. Taken together, telomerase repression in normal renal tissues is attributed to the absence of full-length hTERT transcripts, whereas telomerase activation is achieved via induction of or switch to expression of full-length hTERT mRNA during the oncogenic process of kidneys, and associated with aggressive RCCs.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1078-0432
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
11
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
4331-7
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:15958614-Adult, pubmed-meshheading:15958614-Aged, pubmed-meshheading:15958614-Carcinoma, Renal Cell, pubmed-meshheading:15958614-Cell Line, Tumor, pubmed-meshheading:15958614-DNA-Binding Proteins, pubmed-meshheading:15958614-Enzyme Activation, pubmed-meshheading:15958614-Enzyme-Linked Immunosorbent Assay, pubmed-meshheading:15958614-Female, pubmed-meshheading:15958614-Gene Expression Profiling, pubmed-meshheading:15958614-Gene Expression Regulation, Enzymologic, pubmed-meshheading:15958614-Gene Expression Regulation, Neoplastic, pubmed-meshheading:15958614-Humans, pubmed-meshheading:15958614-Kidney, pubmed-meshheading:15958614-Kidney Neoplasms, pubmed-meshheading:15958614-Male, pubmed-meshheading:15958614-Middle Aged, pubmed-meshheading:15958614-RNA, Messenger, pubmed-meshheading:15958614-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:15958614-Telomerase
pubmed:year
2005
pubmed:articleTitle
Differential expression of full-length telomerase reverse transcriptase mRNA and telomerase activity between normal and malignant renal tissues.
pubmed:affiliation
Division of Urology, Department of Surgery, Karolinska University Hospital, Stockholm, Sweden.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't